Financings in Brief: Anika Research
This article was originally published in The Gray Sheet
Executive SummaryAnika Research: Hyaluronic acid products developer and manufacturer enters an agreement with Axiom Venture Partners under which Axiom will pay Anika $2 mil. in exchange for convertible cumulative preferred stock with a 9% dividend rate and warrants to acquire preferred stock. Preferred stock may be converted one-for-one into common shares by the holder. Anika says that prices for the preferred stock and exercise price of warrants will be "the lower of $2 per share or an amount based upon the average closing price of Anika common stock for a specified period prior to the closing of the financing." The financing is expected to close by May 15...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.